山东赛托生物科技股份有限公司（以下简称"公司"）于 2025 年 9 月 12 日在公司行政大楼西办公楼会议室召开公司 2025 年第一次职工代表大会，审议 通过《关于选举李璐女士为第四届董事会职工代表董事的议案》。 经与会职工代表审议，一致同意选举李璐女士（简历详见附件）为公司第四 届董事会职工代表董事，任期自本次职工代表大会审议通过之日起至公司第四届 董事会任期届满之日止。 李璐女士原为公司第四届董事会董事，本次选举完成后，变更为公司第四届 董事会职工代表董事，公司第四届董事会构成人员不变。 本次选举完成后，公司董事会中兼任公司高级管理人员职务的董事以及由职 工代表担任的董事，总计未超过公司董事总数的二分之一。 证券代码：300583 证券简称：赛托生物 公告编号：2025-036 山东赛托生物科技股份有限公司 关于选举第四届董事会职工代表董事的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《上市公司章程指引》等法律法规和规范性 文件及《山东赛托生 ...

法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号楼 邮编：310008 国浩律师（杭州）事务所 关 于 山东赛托生物科技股份有限公司 2025 年第一次临时股东大会 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二〇二五年九月 赛托生物 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 山东赛托生物科技股份有限公司 2025 年第一次临时股东大会 法律意见书 致：山东赛托生物科技股份有限公司 国浩律师（杭州）事务所（以下简称"本所"）接受山东赛托生物科技股份 有限公司（以下简称"公司"）的委托，指派律师出席公司 2025 ...

2025 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 证券代码：300583 证券简称：赛托生物 公告编号：2025-035 山东赛托生物科技股份有限公司 特别提示： 1、本次股东大会不存在否决议案的情形； 2、本次股东大会不涉及变更前次股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 山东赛托生物科技股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会会议通知于 2025 年 8 月 26 日以公告形式发出，本次股东大会采取现场投 票和网络投票相结合的方式召开。其中，现场会议于 2025 年 9 月 12 日（星期五） 14:30 在公司会议室召开；通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 9 月 12 日 9:15-9:25，9:30-11:30，13:00-15:00。通过深圳证券交易所 互联网系统投票的具体时间为 2025 年 9 月 12 日 9:15-15:00。 本次会议由公司董事会召集，米奇先生主持，公司全体董事、监事、高级管 理人员和见证律师等出席或列席会议。 ...

Group 1 - The company, Saito Bio (300583.SZ), stated on the interactive platform that it currently does not have any formulations suitable for hepatitis [1]

Group 1 - The stock of Saito Bio (300583.SZ) closed at 16.39 yuan, with a decline of 3.87%, resulting in a total market capitalization of 3.109 billion yuan [1] - Saito Bio is currently in a state of breaking its initial public offering price, having been listed on the ChiNext board on January 6, 2017, with an initial offering price of 40.29 yuan per share [1] - The company raised a total of 1.0744 billion yuan through its initial public offering, with a net amount of 1.0256 billion yuan after deducting issuance costs [1][3] Group 2 - Saito Bio has conducted a non-public issuance of 11.6418 million shares at a price of 22.47 yuan per share, raising a total of 261.5904 million yuan [2] - After deducting underwriting and sponsorship fees of 7.8 million yuan, the net amount raised from this issuance was 251.9224 million yuan [2] - The total amount raised by Saito Bio since its listing amounts to 1.336 billion yuan [3]

Core Insights - The financial report of Saito Bio (300583) for the first half of 2025 shows a significant decline in net profit, down 498.8% year-on-year, with total revenue also decreasing by 10.39% [1] Financial Performance Summary - Total revenue for the first half of 2025 was 508 million yuan, a decrease from 567 million yuan in the same period of 2024, representing a decline of 10.39% [1] - The net profit attributable to shareholders was -52.69 million yuan, compared to a profit of 13.21 million yuan in the previous year, marking a decline of 498.8% [1] - The gross profit margin fell to 12.01%, down 53.45% year-on-year, while the net profit margin turned negative at -11.78%, a decrease of 614.8% [1] - Selling, administrative, and financial expenses totaled 68.58 million yuan, accounting for 13.51% of revenue, which is an 18.83% decrease from the previous year [1] - Earnings per share dropped to -0.28 yuan, a decline of 500% compared to the previous year [1] Changes in Financial Items - Right-of-use assets decreased by 84.9% due to a reduction in operating lease real estate business [3] - Lease liabilities saw a decline of 93.32%, also attributed to the decrease in operating lease real estate [3] - Other receivables decreased by 40.13% due to the timely recovery of export tax refunds [3] - Long-term deferred expenses were fully amortized, resulting in a 100% decrease [3] - Sales expenses decreased by 37.45% due to a reduction in the scope of consolidation following the sale of a foreign subsidiary [3] - Management expenses decreased by 32.13% due to both the sale of a foreign subsidiary and optimization of management processes [3] - Income tax expenses decreased by 60.99% due to a reduction in taxable income [3] Cash Flow and Debt Analysis - Net cash increase from cash and cash equivalents rose by 469.23%, driven by increased cash flow from financing activities [4] - The company has a cash flow situation that warrants attention, with cash and cash equivalents to current liabilities at only 32.36% [5] - The interest-bearing debt ratio has reached 26.27%, indicating a significant level of debt [5]

Core Viewpoint - Saito Bio (300583.SZ) released its semi-annual report for 2025, indicating a stable increase in institutional investor holdings, reflecting growing confidence in the company [1] Group 1: Institutional Holdings - As of August 25, 2025, three institutional investors disclosed holdings in Saito Bio A-shares, totaling 43.3048 million shares, which represents 22.83% of the total share capital [1] - The institutional investors include Shandong Runxin Investment Co., Ltd., Huaan CSI 1000 Index Enhanced A, and Huaan CSI 500 Index Enhanced A [1] - Compared to the previous quarter, the total institutional holding percentage increased by 0.01 percentage points [1] Group 2: Public Fund Disclosures - During this period, two new public funds were disclosed compared to the previous quarter, namely Huaan CSI 1000 Index Enhanced A and Huaan CSI 500 Index Enhanced A [1]

Group 1 - The company has approved a profit distribution plan, proposing a cash dividend of 0.1 yuan per 10 shares based on a total of 189,702,126 shares, with no bonus shares issued and no capital reserve conversion [3] - There have been no changes in the controlling shareholder or actual controller during the reporting period [5][6] - The company's operating conditions have not undergone significant changes during the reporting period [7]

Group 1 - The company reported a net profit attributable to ordinary shareholders of -52,687,137.35 yuan for the first half of 2025, while the parent company achieved a net profit of 2,477,250.60 yuan [1] - As of June 30, 2025, the cumulative net profit available for distribution to investors in the consolidated financial statements was 224,112,175.52 yuan [1] - The proposed profit distribution plan is to distribute 1.18 yuan per share (including tax) to all shareholders based on the total share capital of 189,702,126 shares, with no bonus shares or capital reserve conversion [2] Group 2 - The profit distribution plan complies with relevant regulations including the Company Law and accounting standards, ensuring legality, compliance, and reasonableness [2] - The implementation of the profit distribution plan is subject to approval at the company's first extraordinary general meeting of 2025, indicating a level of uncertainty [2]

格隆汇8月25日丨赛托生物(300583.SZ)公布2025年半年度报告，上半年公司实现营业收入5.08亿元，同 比下降10.39%；归属于上市公司股东的净利润-5268.71万元，同比盈转亏；归属于上市公司股东的扣除 非经常性损益的净利润-5348.16万元；基本每股收益-0.28元。 ...